Skip to main content
Premium Trial:

Request an Annual Quote

Aptus Genomics Raises $6.2 Million in Funding

NEW YORK, May 14 – Aptus Genomics added $6.2 million to its coffers in its latest round of financing, the Rockville, Maryland-based company announced Monday.

Aptus develops technology platforms to discover and analyze the function of selected families of human genes. The company, founded in June 2000, is focusing initial efforts on the cell surface receptors super family.

The company is currently completing gene collection and will move to high-throughput functional assays and screening to be used for in-house drug discovery development and future partnership collaborations, Aptus CEO Kevin Chance told GenomeWeb.

The most recent round of funding came from Emerging Technology Partners, the Grosvenor Funds, and VitalBio. Aptus originally raised $1.5 million in seed funding from Emerging Technology Partners in October 2000.

The money will be used for R&D staffing, purchasing equipment, and building infrastructure, said Chance. Aptus currently has two ABI 3700 sequencers.

In June, the company is planning to move its headquarters to Gaithersburg, Maryland.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.